Skip to main content
Signal8

ALPS Medical Breakthroughs ETF (SBIO): ETF

ETF traded on ARCX under symbol SBIO. Quoted in usd.

ALPS Medical Breakthroughs ETF logo

ALPS Medical Breakthroughs ETF

-3.17%$53.87
ARCX:SBIOEquity
AUM $186.27M·YTD --·Yield --
ALPS Medical Breakthroughs ETF logoARCX:SBIO$53.87-3.17%
About SBIO

The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Largest holdings

  1. ORKA Oruka Therapeutics Inc.4.58%
  2. CGON CG oncology Inc.4.33%
  3. MANE VeraDermics Inc.3.56%
  4. DNTH Dianthus Therapeutics Inc.3.37%
  5. EWTX Edgewise Therapeutics Inc.3.27%
  6. TVTX Travere Therapeutics Inc.3.13%
  7. DFTX Definium Therapeutics Inc.2.83%
  8. RLAY Relay Therapeutics Inc.2.61%
  9. XENE Xenon Pharmaceuticals Inc.2.58%
  10. AMLX Amylyx Pharmaceuticals Inc.2.50%
Full holdings, sectors and countries
Dividend History
Benchmark Comparison
Compared against
Performance Returns
Drawdown Chart
Analyst Coverage
Savings Plan Calculator
Total Invested
$70,000
Final Portfolio
$110,086
Total Return
+$40,086
(+57.3%)
Dividends Reinvested
$0
compounded into portfolio
Defaults are seeded from historical performance and trailing twelve-month yield. Past performance is not a forecast. Feel free to adjust any input to model your own assumptions.
ETF Key Metrics
AUM$186.27M
NAV$55.60
Premium/Discount-3.11%
Expense Ratio0.50%
Market Cap$242.95M
Shares Outstanding3.60M
Inception DateDec. 30, 2014
Fund Details
IssuerALPS Funds
Asset ClassEquity
Beta0.95
SectorFinancial Services
DomicileUS
52-Week Range
$44.80$70.85
Current: $53.87
Volume
Volume18.35K
Avg Volume37.51K
Vol/Avg0.49x

30d

25.24K

60d

34.76K

90d

35.84K

Comparable ETFs